Daewon Pharmaceutical대원제약
003220 · KOSPI · ₩003220 · 대원제약
₩7,730▲ ₩90 (1.18%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩605B | ₩598B | ₩527B | ₩479B | ₩354B |
| Cost of sales | ₩333B | ₩311B | ₩270B | ₩241B | ₩178B |
| Gross profit | ₩273B | ₩287B | ₩257B | ₩238B | ₩176B |
| Operating income | ₩3.5B | ₩28B | ₩32B | ₩43B | ₩19B |
| Net income | −₩4B | ₩9B | ₩23B | ₩31B | ₩6.6B |
| Net income to shareholders | −₩1.4B | ₩14B | ₩24B | ₩32B | ₩7B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩614B | ₩583B | ₩508B | ₩454B | ₩430B |
| Current assets | ₩257B | ₩258B | ₩209B | ₩207B | ₩180B |
| Cash and equivalents | ₩47B | ₩17B | ₩30B | ₩27B | ₩42B |
| Total liabilities | ₩339B | ₩299B | ₩244B | ₩205B | ₩211B |
| Current liabilities | ₩216B | ₩201B | ₩183B | ₩128B | ₩102B |
| Borrowings | ₩198B | ₩153B | ₩144B | ₩117B | ₩121B |
| Total equity | ₩275B | ₩285B | ₩264B | ₩249B | ₩218B |
| Shareholders' equity | ₩266B | ₩275B | ₩266B | ₩251B | ₩219B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩42B | ₩30B | ₩52B | ₩33B | ₩22B |
| Capital spending | ₩30B | ₩35B | ₩12B | ₩8B | ₩4.1B |
| Free cash flow | ₩13B | −₩4.8B | ₩39B | ₩25B | ₩18B |
| Dividends paid | ₩6.4B | ₩6.4B | ₩7.3B | ₩4.1B | ₩3.1B |
Consolidated where available. Amounts in won.
Also known as: Daewon Pharmaceutical / 대원제약 / 003220 / KRX:003220
Source: KRX statistical information